Triton Agreement and Precision Study

Inclusion Criteria

• •1. Subjects 18 years of age or older on the date of informed consent
• •2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• •3. Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable)
• •4. IOP ≤ 21 mmHg bilaterally
• •5. BCVA 20/40 or better bilaterally
• •1. Subjects 18 years of age or older on the date of informed consent
• •2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• •3. BCVA 20/40 or better in the study eye
• •4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:
• •1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
• •2. Glaucoma hemi-field test "outside normal limits."
• •5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
• •1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage;
• •2. Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or
• •3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
• •1. Subjects 18 years of age or older on the date of informed consent
• •2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• •3. Subjects presenting at the site with retinal disease
• •4. IOP ≤ 21 mmHg in the study eye
• •5. BCVA 20/400 or better in the study eye
• •6. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others